Drugs / BGP-15
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01069965 | Oct 2010 → Aug 2011 | type 2 diabetes mellitus | N-Gene Research Laboratories, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGP-15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01069965 ↗ |
| Modality | Small molecule | — CHEMBL4747845 ↗ |
| Route | Oral | “Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening” NCT01069965 ↗ |